LH

FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Retrieved on: 
월요일, 5월 6, 2024
FDA, Other Health, Practice Management, Surgery, Managed Care, Oncology, Women, Medical Devices, Hospitals, Men, Biotechnology, Science, Consumer, Research, Health, Medical Supplies, Cancer, Food, Large intestine, Colorectal cancer, Methylation, Death, American Cancer Society, CRC, RNA, LH, Disease, Incidence, Patient, Colonoscopy, Biomarker, Ageing, Vaccine

Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.

Key Points: 
  • Geneoscopy, Inc. , a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
  • ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC.
  • Designated as a Breakthrough Device by the FDA, ColoSense is the first noninvasive colorectal cancer screening test to provide a dynamic view of disease activity by using RNA biomarkers.
  • Colorectal cancer is the second deadliest cancer in the United States.

Labcorp to Webcast Its Annual Meeting of Shareholders

Retrieved on: 
수요일, 5월 8, 2024
Annual general meeting, LH, Webcast

BURLINGTON, N.C., May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m.

Key Points: 
  • BURLINGTON, N.C., May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m.
  • ET and can be viewed online on the Labcorp Investor Relations website .
  • An archived replay of the webcast will be available for one year.

Labcorp Announces Winning Bid for Select Assets of Invitae

Retrieved on: 
목요일, 4월 25, 2024
LH, Hearing

BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

Key Points: 
  • Transaction requires court approval, with confirmation expected on May 6, 2024
    BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.
  • Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
  • Upon completion, Labcorp expects this transaction would generate approximately $275-$300 million in annual revenue with the vast majority in specialty testing areas such as oncology and rare diseases.
  • Through this transaction, Labcorp would acquire assets being auctioned through a voluntary bankruptcy protection process.

Invitae Enters into Agreement with Labcorp for Sale of Business

Retrieved on: 
목요일, 4월 25, 2024
Sale, Customer, FTI Consulting, Partner, OTC, LH, Kirkland & Ellis, Business continuity planning, Employment, Kirkland, Asset, Health, Auction

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration.

Key Points: 
  • Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration.
  • "The agreement with Labcorp marks a significant step in our financial restructuring and supports our efforts to continue to deliver innovative and industry leading products and services for healthcare," said Ken Knight, president and chief executive officer of Invitae.
  • The hearing to approve the sale is currently scheduled for May 6, 2024.
  • With Court approval, as well as customary regulatory approvals and closing conditions, Labcorp and Invitae anticipate completing the sale process in the third quarter of 2024.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Retrieved on: 
월요일, 4월 15, 2024
Neurodegenerative disease, Nerve, Hospital, Blood, AFL, Brain, LH, Glioblastoma, GFAP, TBI, Alzheimer's disease, Disease, Injury, Astrocyte, Physician, Multiple sclerosis, Health, Traumatic brain injury, Biomarker, Glial fibrillary acidic protein, Medical imaging

BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.

Key Points: 
  • The new GFAP test – a first-of-its-kind test to be offered commercially nationwide – offers physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma and injuries like traumatic brain injury (TBI).
  • The biomarker test also expands on Labcorp's comprehensive neurology portfolio, which includes biomarker tests for neurofilament light chain (NfL), pTau181, pTau217 and beta amyloid 42/40.
  • "The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending our leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer.
  • In the context of neurodegenerative disease or injury, astrocytes release GFAP into the blood, allowing brain injury and disease to be assessed through a simple blood draw.

Labcorp Declares Quarterly Dividend

Retrieved on: 
목요일, 4월 11, 2024
LH

BURLINGTON, N.C., April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

Key Points: 
  • BURLINGTON, N.C., April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
  • The dividend will be payable on June 12, 2024, to stockholders of record as of the close of business on May 28, 2024.

Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

Retrieved on: 
수요일, 4월 10, 2024
FDA, Physician, Mpox, Laboratory, Food, CDC, Clinical Laboratory, LH, Collection, Polymerase chain reaction, CLIA, PCR, Patient, Privacy, Virus, Diagnosis, Monkeypox virus, Death, Infection

BURLINGTON, N.C., April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox  PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox. The test is the first mpox at-home collection kit authorized by FDA and is available to physicians to order for patients 18 years of age or older who are suspected of mpox infection.

Key Points: 
  • The test is the first mpox at-home collection kit authorized by FDA and is available to physicians to order for patients 18 years of age or older who are suspected of mpox infection.
  • "The FDA's emergency authorization of Labcorp's Mpox PCR Test Home Collection Kit will enable us to play a vital role within the healthcare community in the early detection and management of mpox," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer.
  • "The collection kit reflects our ongoing commitment to providing critical diagnostic tools to physicians and accessible and convenient testing options to patients."
  • Labcorp will send the test kit directly to patients for at-home collection.

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

Retrieved on: 
금요일, 3월 29, 2024
Genetic testing, Partnership, Physician, Patient, Fertility, Insurance, Inception, FDA, LH, Genetic counseling

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Key Points: 
  • The expansion of this partnership delivers another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient service centers.
  • Additionally, Labcorp offers comprehensive genetic counseling, services for provider questions, and complimentary review of carrier screening results for patients.
  • To improve financial access to genetic carrier screening for the U.S. patient population, Labcorp is contracted with many insurance companies.
  • "Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and Director of Genetic Services at Inception.

Labcorp to Announce First Quarter Financial Results on April 25, 2024

Retrieved on: 
수요일, 3월 27, 2024
Webcast, PIN, LH

BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024.

Key Points: 
  • BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024.
  • The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website .
  • The call will be webcast live on the Labcorp Investor Relations website .
  • To access the webcast recording, visit the Labcorp Investor Relations website .

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Retrieved on: 
수요일, 3월 20, 2024
Diagnosis, Health, Patient, Research, ATN, Blood, LH, Physician, AFL, Dementia, Medical imaging

BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies. Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners.

Key Points: 
  • Labcorp's pTau217 test can be ordered by physicians and used in clinical trials and research by global biopharmaceutical partners.
  • Alzheimer's disease, the most prevalent form of dementia, poses a significant health challenge globally.
  • The ATN Profile provides physicians with an accessible and interpretable blood test to assess pathologies associated with Alzheimer's disease and other neurodegenerative conditions, which can help accelerate the path to diagnosis and intervention.
  • For more information about the pTau217 biomarker and the use of Labcorp's new test in patient care, visit http://www.labcorp.com/alzheimers .